Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

peginterferon beta-1a

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

- PMLiVE

Royalty Pharma mulls bid for Elan

Follows Biogen’s $3.25bn acquisition of Tysabri from Elan

- PMLiVE

Merck to develop biosimilars with Samsung-Biogen joint venture

Agreement with Samsung Bioepis covers several candidates

- PMLiVE

Biogen gains full rights to Tysabri in $3.25bn deal with Elan

Ends decade-long partnership for MS drug

- PMLiVE

Merck KGaA and Opexa enter MS deal

Will develop personalised T-cell based medicine Tcelna

- PMLiVE

Biogen Idec posts solid Q4 results and says more to come

MS drugs Tysabri and Avonex lift sales

- PMLiVE

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

- PMLiVE

Biogen Idec licenses antisense drugs from Isis in $630m deal

Gains neurological and neuromuscular disorder projects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links